N029 Patients experience of advice received on the use of topical therapies in inflammatory bowel disease (IBD) N030 Real benefi
PDF) P698 Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn's disease and ulcerative colitis patients
N-ECCO survey results of nursing practice in caring for patients with Crohn's disease or ulcerative colitis in Europe
Figure 1 | Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review | SpringerLink
Introduction
ECCO | OH Cards NA
Kevin Whelan on Twitter: "Interested to learn more about #IBD? Prof James Lindsay promotes use of the ECCO-e learning platform https://t.co/f6faP7NIRI #IBDdiet #ECCO… https://t.co/veMvbyI8WR"
European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Dis
PDF) P728 Changes in the use of biologics in the treatment of IBD patients over time. Results from a comprehensive Norwegian registry study
PDF) ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease
PDF) P374 Non-alcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors
Home
Journal of Crohn's and Colitis | ScienceDirect.com by Elsevier
Untitled
Home
PDF) P045 The relationship between thiol/disulphide and inflammatory bowel disease
Past Congresses
Congresses & Events
JOURNAL of CROHN'S and COLITIS JOURNAL of CROHN'S and COLITIS
Home
PDF) ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment
10th Congress of ECCO
Home
